Genetic Dimmer Switch May Boost Sepsis Resistance

University of California - Santa Cruz

SANTA CRUZ, Calif. – Researchers who study the cellular mechanisms that lead to uncontrolled immunity responses that cause certain devastating diseases have discovered a molecular mechanism that can sway whether the body survives severe, life-threatening inflammation. The new study appears this week in the Proceedings of the National Academy of Sciences (PNAS).

In the paper, researchers at the University of California, Santa Cruz, report that a specific RNA molecule called Gaplinc acts as a genetic "dimmer switch"—or rheostat—that controls both inflammatory activity and cellular metabolism inside immune cells. This discovery presents a promising new strategy for treating sepsis, which kills at least 20 percent of adults and 10 percent of children who develop the illness, according to the Centers for Disease Control and Prevention (CDC).

Sepsis occurs when the immune system overreacts to an infection, triggering runaway inflammation that damages healthy organs. Currently, clinicians have few treatment options beyond fluids, antibiotics, and supportive care. The new study reveals that Gaplinc, a long non-coding RNA (lncRNA) found in key immune cells known as macrophages, directly regulates host survival during endotoxic shock.

It does this by binding to an enzyme called MCCC1 inside the cell's energy factories, the mitochondria. By attaching to MCCC1, Gaplinc bridges gene expression with metabolic processing. In mouse models where Gaplinc was completely absent, baseline immune genes remained slightly "pre-armed," and circulating blood fats shifted into a protective, "sepsis-resistant" balance.

This boosts helpful lipids called lysophosphatidylcholines while reducing toxic free fatty acids. As a result, 100% of Gaplinc-deficient mice survived lethal bacterial toxin levels that proved fatal to normal mice. Conversely, when Gaplinc was overproduced, baseline immune readiness dropped too low and left the lab mice much more prone to rapid, fatal shock.

The research team says its discovery, that Gaplinc functions as a fine-tuned regulator, presents a new path for treating or preventing sepsis. For instance, transient RNA therapeutics such as lipid nanoparticles could temporarily rebalance Gaplinc levels and reprogram cellular metabolism during acute infection.

"Sepsis is devastating because once that inflammatory cascade spirals out of control, clinicians mostly have to rely on supportive care and hope the patient can weather the storm," said senior author Susan Carpenter, professor of molecular, cell, and developmental biology at UC Santa Cruz. "Instead of trying to completely shut down the immune system during sepsis, leaving patients vulnerable to the underlying infection, targeting Gaplinc could let us fine-tune the body's metabolic resilience to survive the shock."

The persistence of sepsis

The discovery addresses an immense public-health challenge in the United States, where sepsis persists as a leading cause of hospital deaths. At least 350,000 adults and more than 1,800 children die from sepsis annually during hospitalization or after transfer to hospice care. And according to the CDC, sepsis is present in one out of every three hospital deaths across the country.

Sepsis can originate from common bacterial, viral, or fungal infections in the lungs, urinary tract, skin, or gastrointestinal tract. Because existing drugs cannot reliably halt the body's destructive inflammatory cascade once it begins, identifying upstream metabolic regulators like Gaplinc present real promise for life-saving drug development.

Unlocking the role of non-coding RNA

Also co-director of the UCSC RNA Center , Carpenter focuses on long non-coding RNAs, transcripts that make up a vast portion of the human genome but do not encode proteins. Specifically, her team seeks to better understand how lncRNAs direct innate immune responses.

"These findings mark a major advancement in our ongoing investigation into Gaplinc," said Carpenter, whose lab first discovered that the RNA molecule regulates key inflammatory genes driven by a specific protein complex. "Our new study expands this foundation by demonstrating how Gaplinc operates across systemic organ networks and metabolic pathways."

UC Santa Cruz professors David Boyd, in the Department of Molecular, Cell, & Developmental Biology, and Camilla Forsberg, in the Baskin School of Engineering's Department of Biomolecular Engineering, co-authored the study, along with UC Santa Cruz researchers Valeriya Smaliy, Diana Escalona, Steven Liang, Lisa Sudek, Apple Cortez Vollmers, Sol Katzman, Stephanie Smith-Berdan, Eric Malekos, and Alexa Mozqueda.

This research was supported by federal funding from the National Institutes of Health and the National Institute of General Medical Sciences.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.